Notice of Commencement of Preparation for Transition to a Holding Company Structure through Sole-Share Transfer and Change in Fiscal Year Posted Feb 4, 2021
(Timely Disclosure) Notice of Commencement of Preparation for Transition to a Holding Company and Change in Fiscal Year Posted Feb 4, 2021
Santen and Ube Announces U.S. FDA Acceptance of New Drug Application for STN10117 (DE-117) (JAN: Omidenepag Isopropyl) as a Treatment for Patients with Glaucoma and Ocular Hypertension Posted Feb 2, 2021
Santen and Ube Announces Launch of Glaucoma and Ocular Hypertension Treatment EYBELIS Ophthalmic Solution 0.002% in South Korea Posted Feb 1, 2021
Santen Joins the Valuable 500 International Initiative Promoting the Active Participation of People with Disabilities Posted Jan 7, 2021
